2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aminopeptidase
  5. Aminopeptidase Inhibitor

Aminopeptidase Inhibitor

Aminopeptidase Isoform Comparison

Aminopeptidase Inhibitors (94):

Cat. No. Product Name Effect Purity
  • HY-B0134
    Bestatin
    		Inhibitor 99.98%
    Bestatin is a natural, broad-spectrum, and competitive CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase inhibitor. Bestatin has anticancer effects.
  • HY-15695
    Puromycin aminonucleoside
    		Inhibitor 99.86%
    Puromycin aminonucleoside (NSC 3056) is the aminonucleoside portion of the antibiotic puromycin, and used in nephrosis animal models. Puromycin aminonucleoside induces apoptosis. Puromycin aminonucleoside is a reversible inhibitor of dipeptidyl peptidase II and cytosol alanyl aminopeptidase. Puromycin aminonucleoside induces secretion of cell migrasome.
  • HY-113952
    Actinonin
    		Inhibitor 98.37%
    Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces. Actinonin inhibits aminopeptidase M, aminopeptidase N and leucine aminopeptidase. Actinonin is a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. Actinonin also inhibits MMP-1, MMP-3, MMP-8, MMP-9, and hmeprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin is an apoptosis inducer. Actinonin has antiproliferative and antitumor activities.
  • HY-B0494
    Bufexamac
    		Inhibitor 98.47%
    Bufexamac is a selective Ⅱb HDAC (HDAC6, HDAC10) and LTA4H dual inhibitor, with Kds of 0.53 µM and 0.22 µM for HDAC6 and HDAC10. Bufexamac is a nonsteroida anti-inflammatory drug.
  • HY-176778A
    (rac)-BDM88951
    		Inhibitor 98.64%
    (rac)-BDM88951 is the racemate of BDM88951 (HY-176778). BDM88951 (Compound 4 d) is a selective ERAP2 inhibitor with an IC50 of 19 nM. BDM88951 significantly inhibits antigen presentation in HEK cells. BDM88951 can be used for research on autoimmune diseases and cancer.
  • HY-P11642A
    Sialorphin TFA
    		Inhibitor
    Sialorphin TFA is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin TFA blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin TFA regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin TFA exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin TFA also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin TFA is also a copper (II) ion-binding ligand. Sialorphin TFA has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease.
  • HY-14807
    Tosedostat
    		Inhibitor 99.68%
    Tosedostat (CHR-2797) is an orally active aminopeptidase inhibitor. CHR-2797 exerts antiproliferative effects against a range of tumor cell lines.
  • HY-101932
    TNP-470
    		Inhibitor 99.87%
    TNP-470 is a methionine aminopeptidase-2 inhibitor and also an angiogenesis inhibitor.
  • HY-133125
    ERAP1-IN-1
    		Inhibitor 98.77%
    ERAP1-IN-1 is an endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitor. ERAP1-IN-1 competitively inhibits ERAP1 activity towards a nonamer peptide representative of physiological substrates.
  • HY-137298
    LYS006
    		Inhibitor 98.41%
    LTA4H-IN-1 is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC50 of 2 nM. LTA4H-IN-1 can be used for the research of inflammatory and autoimmune disorders.
  • HY-103226
    SC-57461A
    		Inhibitor 99.93%
    SC-57461A is a potent, orally active, nonpeptide, and selective inhibitor of Leukotriene A4 (LTA4) hydrolase with IC50s of 2.5 nM, 3 nM, and 23 nM for recombinant human, mouse, and rat LTA4 hydrolase, respectively.
  • HY-109058
    Firibastat
    		Inhibitor 98.0%
    Firibastat (QGC001), an orally active brain penetrating proagent of EC33, is a first-in-class brain aminopeptidase A (APA) inhibitor (Ki=200 nM). Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats.
  • HY-115194
    Amastatin hydrochloride
    		Inhibitor 99.43%
    Amastatin hydrochloride is a slow, tight binding, competitive aminopeptidase (AP) inhibitor with Ki values of 0.26 nM, 30 nM, 52 nM for Aeromonas aminopeptidase, cytosolic leucine aminopeptidase, microsomal aminopeptidase.
  • HY-117738
    Benarthin
    		Inhibitor
    Benarthin is a catechol-type siderophore isolated from the marine actinomycete Streptomyces YM5-799 that exhibits iron-chelating properties.
  • HY-130553
    β-Spaglumic acid
    		Inhibitor 99.97%
    β-Spaglumic acid (β-NAAG) is a competitive NAAG peptidase inhibitor (Ki=1 µM) that protects spinal cord neurons from excitotoxicity and hypoxic damage. β-Spaglumic acid is also a selective mGluR3 antagonist (mGluR3 receptor functions to regulate activity-dependent synaptic potentiation in the hippocampus). β-Spaglumic acid can be used in neuroprotection-related studies.
  • HY-N2150
    Psammaplin A
    		Inhibitor
    Psammaplin A is a marine metabolite. Psammaplin A is a selective HDAC1 (IC50: 45 nM), DNA methyltransferases (IC50: 18.6 nM) and aminopeptidase N (APN) (IC50: 18 μM) inhibitor. Psammaplin A also inhibits DNA topoisomerase and farnesyl protein transferase. Psammaplin A is a PPARγ activator and induces apoptosis. Psammaplin A has antitumor and anti-inflammatory activities. Psammaplin A has antibacterial activity against Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity. Psammaplin A inhibits angiogenesis.
  • HY-17625
    Acebilustat
    		Inhibitor 99.67%
    Acebilustat (CTX-4430) is a leukotriene A4 hydrolase inhibitor, used for an oral antiinflammatory agent.
  • HY-W015876
    L-Leucinol
    		Inhibitor 99.53%
    L-Leucinol ((+)-Leucinol) is a competitive aminopeptidase inhibitor with a Ki value of 17 μM. As a dietary intake inhibitor, L-Leucinol reduces the basal dietary leucine intake in rats via microinjection into the rat anterior piriform cortex.
  • HY-139907B
    DG013A formate
    		Inhibitor 99.57%
    DG013A (formate) is a phosphinic acid tripeptide mimetic inhibitor. DG013A (formate) displays significantly weak affinity for both ERAP1 (IC50=33 nM) and ERAP2 (IC50=11 nM). DG013A (formate) can be used for the research of autoimmune disease and cancer.
  • HY-151518
    Aminopeptidase-IN-1
    		Inhibitor 98.25%
    Aminopeptidase-IN-1 (compound 16o) is an insulin-regulated aminopeptidase (IRAP) inhibitor with an Ki value of 7.7 μM. Aminopeptidase-IN-1 inhibits catalytic activity of IRAP.Aminopeptidase-IN-1 can be used for the research of memory impairments.